Withaferin-A Protects the Nigral Dopamine Neuron and Recovers Motor Activity in Aged Rats

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Aging leads to motor deficits and neurodegeneration, particularly affecting dopamine (DA) neurons in the substantia nigra (SN) and striatum (ST).
• Tyrosine hydroxylase (TH) enzyme levels are critical indicators of dopaminergic neuron health and function.

Purpose of the Study:

• To evaluate the neuroprotective effects of Withaferin-A (WA) on DA neurons in aged rats.
• To assess WA's impact on age-related motor impairments and neuronal structural integrity.

Main Methods:

• Aged and young Wistar albino rats were treated with WA (50 mg/kg) or vehicle.
• Motor behavior was analyzed using rotarod tests and stride length measurements.
• Histological, histomorphometrical, and immunohistological analyses were performed on brain tissues to assess neuronal diameter, density, volume, and TH enzyme levels.

Main Results:

• Aged rats exhibited significant motor impairments, reduced stride length, and decreased neuronal diameter, density, and volume in the SN compared to young rats.
• A marked reduction in TH enzyme levels was observed in the SN and ST of aged rats.
• WA supplementation significantly reversed these structural and functional deficits in aged rats, restoring motor function and neuronal health.

Conclusions:

• Withaferin-A (WA) demonstrates significant neuroprotective potential against age-related motor degenerative changes.
• WA treatment attenuates neuronal loss and functional decline in the substantia nigra and striatum of aged rats.
• WA is a promising therapeutic agent for mitigating age-associated neurodegeneration and motor dysfunction.